LANA PL
Alternative Names: LANA AS; LANA-PLLatest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Antlia Bioscience
- Developer Antlia Bioscience; Karolinska Institute
- Class Antiasthmatics; Antihypertensives; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic obstructive pulmonary disease; Pulmonary hypertension
- No development reported Asthma
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation, Aerosol)
- 19 Jan 2021 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation) before January 2021 (Antlia Bioscience's pipeline, January 2021)
- 19 Jan 2021 Preclinical trials in Pulmonary hypertension in USA (Inhalation) before January 2021 (Antlia Bioscience's pipeline, January 2021)